David Uehling

4.6k citations

46 papers · 3.2k indexed · 1 hit paper · h-index 27

Impact in

Molecular Biology top 5%
- Signaling Pathways in Disease
- Melanoma and MAPK Pathways
- Cancer therapeutics and mechanisms
Oncology top 5%
- Peptidase Inhibition and Analysis

Papers in

Organic Chemistry 15
- Asymmetric Synthesis and Catalysis 5
- Synthesis and biological activity 4
Oncology 13
- HER2/EGFR in Cancer Research 4
- Cancer-related Molecular Pathways 4

Co-authors: Matthew W. Harding Stuart L. Schreiber Andrzej Gałat Clayton H. Heathcock Rima Al‐awar Tarek Sammakia Masashi Nakatsuka John A. Ragan
Journals: Bioorganic & Medicinal Chemistry Letters (7 papers)Journal of Medicinal Chemistry (7 papers)Journal of Biological Chemistry (3 papers)The Journal of Organic Chemistry (3 papers)Journal of the American Chemical Society (2 papers)
Partner nations: Canada United States Italy

In The Last Decade

David Uehling

46 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase 1989 · 1.2k citations

Peers

Countries citing papers authored by David Uehling

Since Specialization

Citations

This map shows the geographic impact of David Uehling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Uehling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Uehling more than expected).

Fields of papers citing papers by David Uehling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Uehling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Uehling. The network helps show where David Uehling may publish in the future.

Co-authors

The 25 scholars most cited alongside David Uehling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Uehling Line = papers co-authored together David Uehling links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation Cancer Discovery ·Mary M. Mader, Joachim Rudolph, Ingo V. Hartung, David Uehling, Paul Workman, William J. Zuercher	2023	5
2	An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma Journal of Neuro-Oncology ·Ashley Adile, David Bakhshinyan, Yujin Suk, David Uehling, Mehakpreet Saini, Asma M. Aman, Jakob Magolan, Minomi Subapanditha, Dillon McKenna, Chirayu Chokshi, Neil Savage, Michelle Kameda-Smith, Chitra Venugopal, Sheila K. Singh	2023	2
3	G protein–receptor kinases 5/6 are the key regulators of G protein–coupled receptor 35–arrestin interactions Journal of Biological Chemistry ·Amlan Ganguly, Tezz Quon, Laura Jenkins, Babu Joseph, Rima Al‐awar, Andy Chevigné, Andrew B. Tobin, David Uehling, Carsten Hoffmann, Julia Drube, Graeme Milligan	2023	5
4	G protein–coupled receptor kinase 6 (GRK6) regulates insulin processing and secretion via effects on proinsulin conversion to insulin Journal of Biological Chemistry ·Matthew J. Varney, Wouter Steyaert, Paul Coucke, Joris Delanghe, David Uehling, Babu Joseph, Richard Marcellus, Rima Al‐awar, Jeffrey Benovic	2022	5
5	Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma Journal of Medicinal Chemistry ·David Uehling, Babu Joseph, Kim Chan Chung, Andrew X. Zhang, Spencer Ler, Michaël Prakesch, Gennady Poda, Julie Grouleff, Asma M. Aman, Taira Kiyota, Chungyee Leung-Hagesteijn, John David Konda, Richard Marcellus, Carly Griffin, Ratheesh Subramaniam, Ayome Abibi, Craig A. Strathdee, Methvin Isaac, Rima Al‐awar, Rodger E. Tiedemann	2021	16
6	Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma Clinical Cancer Research ·Xueqing Lun, J. Connor Wells, Natalie Grinshtein, Jennifer C. King, Xiaoguang Hao, Ngoc-Ha Dang, Xiuling Wang, Asma M. Aman, David Uehling, Alessandro Datti, Jeffrey L. Wrana, Jacob C. Easaw, Artee Luchman, Samuel Weiss, J. Gregory Cairncross, David R. Kaplan, Stephen M. Robbins, Donna L. Senger	2016	169
7	Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay Stem Cell Reports ·Lamis Hammoud, Jessica R. Adams, Amanda J. Loch, Richard Marcellus, David Uehling, Asma M. Aman, Christopher Fladd, Trevor D. McKee, Christine E.B. Jo, Rima Al‐awar, Sean E. Egan, Janet Rossant	2016	14
8	Recent progress on MAP kinase pathway inhibitors Bioorganic & Medicinal Chemistry Letters ·David Uehling, Philip A. Harris	2015	46
9	shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer Cancer Research ·Tao Deng, Jeff C. Liu, Philip E.D. Chung, David Uehling, Asma M. Aman, Babu Joseph, Troy Ketela, Zhe Jiang, Nathan F. Schachter, Robert Rottapel, Sean E. Egan, Rima Al‐awar, Jason Moffat, Eldad Zacksenhaus	2014	29
10	Combined deletion of P ten and p53 in mammary epithelium accelerates triple‐negative breast cancer with dependency on e EF 2 K EMBO Molecular Medicine ·Jeff C. Liu, Véronique Voisin, Sharon Wang, Dong‐Yu Wang, Robert A. Jones, Alessandro Datti, David Uehling, Rima Al‐awar, Sean E. Egan, Gary D. Bader, Ming‐Sound Tsao, Tak W. Mak, Eldad Zacksenhaus	2014	84
11	Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions PLoS ONE ·Alastair J. King, Marc R. Arnone, Maureen R. Bleam, Katherine G. Moss, Jingsong Yang, Kelly E. Fedorowicz, Kimberly N. Smitheman, Joseph A. Erhardt, Angela Hughes‐Earle, Laurie S. Kane-Carson, Robert H. Sinnamon, Hongwei Qi, Tara Rheault, David Uehling, Sylvie Laquerre	2013	163
12	New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia Radiotherapy and Oncology ·Dan Cojocari, Ravi N. Vellanki, Brandon Sit, David Uehling, Marianne Koritzinsky, Bradly G. Wouters	2013	35
13	TWEAK and cIAP1 Regulate Myoblast Fusion Through the Noncanonical NF-κB Signaling Pathway Science Signaling ·Emeka K. Enwere, Janelle Holbrook, Rim Lejmi-Mrad, Jennifer Vineham, Kristen Timusk, Baktharaman Sivaraj, Methvin Isaac, David Uehling, Rima Al‐awar, Eric C. LaCasse, Robert G. Korneluk	2012	67
14	Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells Cancer Research ·Natalie Grinshtein, Alessandro Datti, Mayumi Fujitani, David Uehling, Michaël Prakesch, Methvin Isaac, Meredith S. Irwin, Jeffrey L. Wrana, Rima Al‐awar, David R. Kaplan	2011	76
15	Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Alex G. Waterson, Kimberly G. Petrov, Keith R. Hornberger, Robert D. Hubbard, Douglas M. Sammond, Stephon C. Smith, Hamilton D. Dickson, Thomas R. Caferro, Kevin W. Hinkle, Kirk L. Stevens, Scott H. Dickerson, David W. Rusnak, Glenn Spehar, Edgar R. Wood, Robert Griffin, David Uehling	2009	33
16	Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Tara Rheault, Thomas R. Caferro, Scott H. Dickerson, Kelly H. Donaldson, Michael D. Gaul, Aaron S. Goetz, Robert J. Mullin, Octerloney B. McDonald, Kimberly G. Petrov, David W. Rusnak, Lisa M. Shewchuk, Glenn Spehar, Anne T. Truesdale, Dana E. Vanderwall, Edgar R. Wood, David Uehling	2008	72
17	Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines Bioorganic & Medicinal Chemistry Letters ·Robert D. Hubbard, Scott H. Dickerson, Holly K. Emerson, Robert Griffin, Michael J. Reno, Keith R. Hornberger, David W. Rusnak, Edgar R. Wood, David Uehling, Alex G. Waterson	2008	29
18	Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Alex G. Waterson, Kirk L. Stevens, Michael J. Reno, Yuemei Zhang, Eric E. Boros, Frédéric Bouvier, Abdullah Rastagar, David Uehling, Scott H. Dickerson, Bryan R. Reep, Octerloney B. McDonald, Edgar R. Wood, David W. Rusnak, Krystal J. Alligood, Sharon K. Rudolph	2006	19
19	Synthesis, Topoisomerase I Inhibitory Activity, and in Vivo Evaluation of 11-Azacamptothecin Analogs Journal of Medicinal Chemistry ·David Uehling, Suganthini Nanthakumar, Dallas K. Croom, David L. Emerson, Peter P. Leitner, Michael J. Luzzio, Gordon D. McIntyre, Bradley Morton, S. Profeta	1995	46
20	Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase I Journal of Medicinal Chemistry ·Michael J. Luzzio, Jeffrey M. Besterman, David L. Emerson, Michael G. Evans, Karen Lackey, Peter Leitner, Gordon D. McIntyre, Bradley Morton, Peter L. Myers, Michael Peel, Jay M. Sisco, Daniel D. Sternbach, Wei‐Qin Tong, Ann Truesdale, David Uehling, A. Vuong, Julie Yates	1995	122

About David Uehling

David Uehling is a scholar working on Organic Chemistry, Oncology, Genetics, Molecular Biology and Toxicology, having authored 46 papers that have together received 3.2k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (6 papers), Melanoma and MAPK Pathways (5 papers), Asymmetric Synthesis and Catalysis (5 papers), HER2/EGFR in Cancer Research (4 papers), Cancer-related Molecular Pathways (4 papers), Glioma Diagnosis and Treatment (4 papers), Cancer therapeutics and mechanisms (4 papers) and Synthesis and biological activity (4 papers). The work is most often cited by research in Molecular Biology (2.3k citations), Oncology (800 citations), Toxicology (96 citations), Organic Chemistry (756 citations) and Immunology (411 citations). David Uehling has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include Matthew W. Harding, Stuart L. Schreiber, Andrzej Gałat, Clayton H. Heathcock, Stuart L. Schreiber, Rima Al‐awar, Tarek Sammakia, Masashi Nakatsuka, John A. Ragan and David B. Smith. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Journal of Biological Chemistry, The Journal of Organic Chemistry and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact